1121 related articles for article (PubMed ID: 29561981)
21. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of controlled attenuation parameter in a health check-up cohort.
Kwak MS; Chung GE; Yang JI; Yim JY; Chung SJ; Jung SY; Kim JS
Liver Int; 2018 May; 38(5):915-923. PubMed ID: 28940824
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
[TBL] [Abstract][Full Text] [Related]
24. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
[TBL] [Abstract][Full Text] [Related]
25. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
[TBL] [Abstract][Full Text] [Related]
26. Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease.
Naveau S; Voican CS; Lebrun A; Gaillard M; Lamouri K; Njiké-Nakseu M; Courie R; Tranchart H; Balian A; Prévot S; Dagher I; Perlemuter G
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1022-1030. PubMed ID: 28570343
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
28. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
[TBL] [Abstract][Full Text] [Related]
29. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
[TBL] [Abstract][Full Text] [Related]
30. Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.
Ahn JM; Paik YH; Min SY; Cho JY; Sohn W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut Liver; 2016 Mar; 10(2):295-302. PubMed ID: 26347511
[TBL] [Abstract][Full Text] [Related]
31. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
[TBL] [Abstract][Full Text] [Related]
32. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.
Agarwal L; Aggarwal S; Shalimar ; Yadav R; Dattagupta S; Garg H; Agarwal S
Obes Surg; 2021 Feb; 31(2):617-626. PubMed ID: 33052552
[TBL] [Abstract][Full Text] [Related]
33. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.
Seto WK; Hui RWH; Mak LY; Fung J; Cheung KS; Liu KSH; Wong DK; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):575-583.e2. PubMed ID: 28970146
[TBL] [Abstract][Full Text] [Related]
34. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
36. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
[TBL] [Abstract][Full Text] [Related]
37. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
38. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
de Lédinghen V; Hiriart JB; Vergniol J; Merrouche W; Bedossa P; Paradis V
Dig Dis Sci; 2017 Sep; 62(9):2569-2577. PubMed ID: 28577247
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
[TBL] [Abstract][Full Text] [Related]
40. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center.
Sandra S; Lesmana CRA; Purnamasari D; Kurniawan J; Gani RA
Diabetes Metab Syndr; 2019; 13(1):424-428. PubMed ID: 30641737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
